WORLD-VAPERS’-ALLIANCE
30.6.2021 00:32:10 CEST | Business Wire | Press release
The World Vapers’ Alliance is today launching a major global campaign – ‘Back Vaping. Beat Smoking ’ - with the goal of shaping international public health policies and saving 200 million lives worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006043/en/
“The weight of research and real-world evidence shows that progressive vaping policies can help millions of smokers to quit. Yet vaping remains under threat as decision-makers face pressure from anti-vaping organisations. Our campaign will make sure the evidence and the voices of vapers are heard, so that Governments will take the opportunity to save 200 million lives”, said Michael Landl, Director of the World Vapers’ Alliance.
2021 is a critical year for public health policies globally. Two major milestones will determine if Governments grab the opportunity to save 200 million lives, or decide to limit smokers’ access to life-changing quit tools. The global ‘COP9’ conference will set the direction for anti-smoking and vaping policies worldwide. And the EU’s ‘Tobacco Products Directive’ laws, currently being discussed in Brussels, will act as the benchmark for vaping policies globally.
“There is a risk that global leaders at COP 9 and at EU level - under pressure from anti-vaping activists - will introduce laws that would treat vaping the same as smoking” according to Landl. “This would spell disaster for vapers, for smokers and for public health. Millions of vapers may be forced back to smoking due to tax hikes, flavour bans, and other restrictions on vaping accessibility.”
“If they ignore that vaping is 95% less harmful than smoking and has already helped millions to quit smoking, then they will miss a golden opportunity to save lives. Nearly 200 million lives can be saved if the right vaping policies are introduced, and 2021 is an absolutely critical year if this is to be achieved,” Michael Landl added.
The World Vapers’ Alliance is launching a global campaign today to make sure that the voices of the millions of vapers who have successfully beaten smoking thanks to vaping are heard. The Back Vaping. Beat Smoking campaign will deliver a clear message to all the decision-makers around the world: The best way we can beat smoking is to promote vaping as part of public health policies.
“It’s vital that vapers' voices are heard. That’s why we’re taking our campaign out on the road, across Europe and around the world. Our campaign will combine digital and real-world activism to ensure that Governments take the opportunity to ‘Back Vaping. Beat Smoking’,” Michael Landl concluded.
ENDS
---
Notes to editor:
- The World Vapers’ Alliance represents 23 vapers associations as well as 14.000 individual vapers from all over the world.
- Next FCTC COP9 meeting will be held 8–13 November 2021.
- The European Commission’s report on assessing the application of the rules laid down in the Tobacco Products Directive 2014/40/EU (TPD) was published on 20 May 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629006043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio
Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership15.9.2026 11:16:00 CEST | Press release
Live in six markets within twelve weeks of launch, with a 19,000-person waitlist Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/ Axo Longevity preventive health membership The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21. Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 11:00:00 CEST | Press release
Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins Chiesi from Flagship Pioneering. Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
